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ABSTRACT 
Reactive oxygen species (ROS) are oxygen containing reactive molecules generated as by-products of 
cellular metabolism. At physiological concentrations, ROS acts as secondary messengers in cellular 
signaling transduction, but excessive amounts of ROS result in oxidative stress and cellular damage. 
Several antioxidant enzyme systems include the thioredoxin (Trx)- and glutathione (GSH)-dependent 
systems together with superoxide dismutases and catalases may act in concert to protect cells and 
organisms from the toxic effects of excessive ROS. Mammalian thioredoxin reductase 1 (TrxR1), 
which is a cytosolic selenoprotein with a selenocysteine (Sec, U) residue in a conserved C-terminal 
GCUG motif, catalyzes the reduction of thioredoxin using NADPH and is known to be involved in 
antioxidant defense, redox regulation and cell proliferation. This thesis has focused on studying 
multiple aspects of cellular events and signaling pathways that are modulated by TrxR1.   
Paper I. The Sec residue in the C-terminal motif of TrxR1 is highly nucleophilic and can be easily 
targeted by electrophiles. In this study, we found the mutant p53 activator and anticancer drug lead 
named APR-246 (PRIMA-1Met) targeted and inhibited both recombinant and cellular TrxR activity. The 
inhibited TrxR1 still maintained its NADPH oxidase activity, which thus could contribute to the 
oxidative stress and cell death that are triggered by APR-246. Our findings provide insights into the 
p53 independent cytotoxicity mechanisms of APR-246 on tumor cells. 
Paper II. In this study, we used thiophosphate (SPO3) and selenite to modulate the Sec incorporation 
into TrxR1 in mammalian cells. We found that SPO3 promoted expression of Sec-to-cysteine 
substituted forms of TrxR1 and, conversely, selenite increased Sec incorporation in TrxR1. SPO3 
treatment also attenuated cisplatin induced toxicity on A549 and HCT116 cells, while selenite 
supplementation sensitized NIH 3T3 cells to cisplatin but decreased the dependence of these cells on 
GSH. Taken together, these results show that the selenium status of cells can modulate the cytotoxicity 
of drugs that target TrxR1 and the glutathione dependence of the cells. 
Paper III. Here we utilized Txnrd1 depleted (Txnrd1-/-) mouse embryonic fibroblasts (MEFs) and 
observed massive cell death upon cultured at low-density in high-glucose medium. The cell death was 
linked to excessive H2O2 production promoted by high-glucose metabolism. Reconstitution of the cells 
with Sec-containing TrxR1, but not with the Sec-to-Cys substituted variant, rescued the MEFs from 
this lethality. These results show that Sec-containing TrxR1 is essential to maintain self-sufficiency of 
MEFs under high-glucose conditions, due to an essential role in control of glucose-derived H2O2 
production. This study is, to our knowledge, the first time identified an essential biological role of Sec-
containing TrxR1 that cannot be sustained by the Cys-mutant of the enzyme.    
Paper IV. Txnrd1-/- MEFs revealed a strong increase of spontaneous lipogenesis and hormonally 
induced adipocyte differentiation. The highly promoted adipocyte differentiation capacity was due to 
unlimited mitotic clonal expansion capacity and dramatically upregulated PPARγ expression. These 
effects were likely to be connected to increased oxidative signaling in Txnrd1-/- MEFs, because NAC 
treatment abolished the adipocyte differentiation by blocking mitotic clonal expansion. An increased 
Akt signaling in Txnrd1-/- MEFs induced by decreased cellular PTEN activity and increased ROS, also 
contributes to the enhanced adipogenesis. These results suggest that the selenoprotein TrxR1 suppress 
adipocyte differentiation through inhibition insulin signaling events, mitotic clonal expansion and 
PPARγ expression.  
In summary, this study shows that TrxR1 plays an essential role in antioxidant defense, regulation of 
adipocyte differentiation and servers as an anticancer drug target.   
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1 INTRODUCTION 
1.1 THE ORIGINS OF OXYGEN AND EVOLUTION OF AEROBIC LIFE 
About four and a half billion years ago, the earth was formed by accretion from the solar 
nebula [1]. The meteorites we have, which share the highest similarity to the material from 
the very beginning of earth, are highly reduced. The original atmosphere under this reducing 
environment would contain a mixture of hydrogen (H2), methane (CH4), nitrogen (N2) and 
ammonia (NH3), with small amounts of carbon dioxide (CO2), carbon monoxide (CO), and 
hydrogen sulfide (H2S) etc. Under these circumstances, oxygen (O2) could not be present in 
more than a few parts per million [2]. However, how does the organic life evolve from this 
environment and what is the energy source used for the synthesis of original organic 
compounds?  
Sunlight is the main energy source, but only a small fraction with short wavelength can be 
absorbed by CH4, NH3, H2O, CO2, and so on. UV light is probable, however, most of the 
photochemical reactions at these low wavelengths would have happened in upper 
atmosphere, so that the compounds formed might have been decomposed by this UV light 
before reaching the oceans. Therefore, lightning is believed to be an important source of 
energy that occurs closer to the oceans [2]. During the 1950s, Stanley Miller and Harold Urey 
passed electric sparks that simulating lightning through a gas mixture of  (H2), methane 
(CH4), and ammonia (NH3). After collecting the end-produces, they found a complex mixture 
of organic compounds, including different types of amino acids, which are the components of 
protein and building blocks of life. These reactions are believed to turn the early ocean into a 
soup containing all organic precursors of live. The only ingredients needed for life creation 
out of this soup are chance and time, both of which are limitless. It seems that it took billions 
of years to form the life since the first fossils of large animals is from half a billion years ago 
[3].     
The first organisms are presumably evolved in O2 free atmosphere. For these organisms, O2 
would have severe toxic effects to them since they have few, if any, antioxidants, to protect 
against O2. These O2-hating organisms are called anaerobic. Yeasts and many other single 
cell organisms live on anaerobic respiration (fermentation) for energy production with simple 
structure, which may present the ancient life. Subsequently, the evolution of the first oxygen-
evolving photosynthetic bacteria (cyanobacteria) starts changing the components of 
atmosphere. Cyanobacteria evolved to utilize the sunlight energy to break down water. They 
used hydrogen equivalents to drive their metabolism, and released the byproducts O2 to the 
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atmosphere. The accumulation of O2 has two advantages: it formed the ozone (O3) layer in 
the stratosphere that protected the organisms from UV radiation damage, which may have 
helped the life to move from the sea to the land; in addition, ferrous iron (Fe2+) reacts with 
hydrogen peroxide (H2O2) to produce super toxic hydroxyl radical (OH.) (Fenton reaction, 
see details in section 1.2.2). So life that use O2 for energy production (aerobic) would be 
difficult to be evolved with abundant Fe2+ around. High amount of O2 in the atmosphere 
precipitated Fe2+ from water by forming insoluble Fe3+ complexes, leaving the sea and river 
suitable for life with trace amounts of soluble iron today [4].   
"Excessive amount of O2 was by far the greatest crisis on earth", wrote by professor Lynn 
Margulis at University of Massachusetts in 1986. Microorganisms that had no defense system 
against this toxic gas died out quickly. The resistant organisms propagated and quickly 
replaced the sensitive strains on the surface of the earth. The survivors began to develop 
antioxidant defense systems to protect against the toxicity of O2 [5]. The adaptation to O2 
further evolved the organisms to have metabolic transformations, utilized different 
oxygenases for biosynthesis. Further, they started using O2 for energy production (aerobic 
respiration), which increased the ATP production efficiency dramatically. After the 
development of aerobic respiration, multicellular organisms were subsequently evolved with 
highly efficient energy production. Evolving such systems could ensure controlled 
distribution of O2 to the body: for example, most parts in human body are never exposed to 
the high amount of O2 in atmosphere (approx. 21%) due to a much lower O2 concentration in 
blood [4].  
The 21% O2 content in atmosphere is believed to be formed already half billion years ago by 
the outcome of a sustainable natural balance. When the O2 levels are too high, it will suppress 
the plant growth, which then results in a lower amount of O2 production by the decrease of 
photosynthesis. On the contrary, if the O2 levels decreases, the animals would suffocate, 
which leads to less consumption of O2. Thereby, the nature regulates the atmospheric oxygen 
content through a dynamic equilibrium [3].  
1.2 REACTIVE OXYGEN SPECIES (ROS) 
Evolution of aerobic respiration in organisms inevitably causes production of reactive oxygen 
species (ROS), referring to oxygen containing reactive molecules including superoxide (O2.-), 
hydrogen peroxide (H2O2), hydroxyl radical (OH.), singlet oxygen (1O2), hypochlorous acid 
(HOCl), nitric oxide (NO) and peroxynitrite (OONO-) [6, 7]. Some of these molecules are 
highly reactive, for example, hydroxyl radical can easily cause oxidative damage to proteins, 
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DNA, and lipids; however, some of them are relatively inert, such as superoxide and 
hydrogen peroxide [7]. Physiological concentrations of ROS act as secondary messengers in 
cellular signaling by modulating the activities of protein kinases, phosphatases and 
transcription factors. However, excessive amount of ROS causes cell damage and cell death 
[8].  
1.2.1 Sources of ROS  
Various organelles and enzyme systems are sources of ROS generation in mammalian cells, 
including mitochondrion, endoplasmic reticulum (ER), peroxisome, NADPH oxidase, 
xanthine oxidase (XO), nitric oxide synthase (NOS), lipoxygenase, cyclooxygenase (COX), 
and cytochrome P450 monooxygenase (P450) [9], some of which are further discussed 
below: 
1.2.1.1 Mitochondria  
Mitochondria have been known to be an important generator of intracellular ROS for decades 
[5]. During mitochondrial respiration, electron donors in tricarboxylic acid (TCA) cycle 
donate electrons to mitochondrial electron transport chain, which contains five protein 
complexes named complex I-V respectively. Many studies show that mitochondrial ROS are 
formed predominantly at complex I, coenzyme Q or complex III, which can donate electrons 
one at a time to oxygen molecules and thereby generate superoxide (Fig. 1). The 
mitochondrial isoform of superoxide dismutase (MnSOD) converts superoxide to hydrogen 
peroxide, which is less reactive and can be degraded to H2O and O2 by antioxidant enzymes 
glutathione peroxidases (GPxs), peroxiredoxins (Prxs) or catalases [8, 10] (see section 1.3 for 
more details).  
Xiaoxiao Peng 
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Figure 1. ROS generation through mitochondrial electron transport chain. Mitochondria 
consist of outer mitochondrial membrane (OMM), inner mitochondrial space, inner 
mitochondrial membrane (IMM) and matrix. Mitochondrial electron transport chain is 
located at IMM and consists of complex I to V. NADH and FADH2 are the electron donors 
generated by TCA cycle and give electrons to complex I or II respectively. Electrons are then 
passed to coenzyme Q, complex III and finally complex IV for the reduction of O2 to H2O. 
This process generates a H+ voltage gradient across the mitochondrial membrane. The energy 
from this voltage gradient drives the synthesis of ATP by complex V (ATP synthase). 
Alternatively, uncoupling proteins (UCPs) can diminish the voltage gradient to generate heat 
to control the rate of ATP generation. Single electron leakage from complex I, coenzyme Q 
or complex III reduces O2 to superoxide intermediate. Mitochondrial superoxide dismutase 
(MnSOD) converts this reactive species to hydrogen peroxide, which will further be degraded 
to H2O and O2 by GPxs, Prxs and catalases. The figure is modified from Finkel [8].    
1.2.1.2 Peroxisome  
Another oxygen consumption organelle in the cells is the peroxisome. It was first described 
that in the peroxisome respiratory pathway, electrons are transferred from various metabolites 
to reduce O2 to H2O2 with release of heat instead of production of ATP [11]. The main 
metabolic processes contributing to the generation of ROS in peroxisomes are catalyzed by 
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oxidases such as acyl-coA oxidases, urate oxidase and xanthine oxidase, which may 
contribute to 35% of all hydrogen peroxide generated in rat liver [12]. In addition, iron and 
copper ions are abundant in peroxisomes and can catalyze the formation of hydroxyl radical 
in the Fenton reaction (see below for more details) [13].   
1.2.1.3 Endoplasmic reticulum 
ER is the cellular compartment in which proper protein folding and disulfide formation of 
proteins take place. These processes are dependent on the oxidizing environment in the lumen 
of ER with a high ratio of oxidized to reduced glutathione (GSSG/GSH). It estimates that 
25% of the cellular ROS is generated from disulfide bonds formation in the ER during 
protein folding. The plausible mechanism is that during disulfide bonds formation, ER 
oxidoreductin 1 (ERO1) and protein disulfide isomerase (PDI) transfer electrons from free 
thiol groups to oxygen and thereafter form ROS [14]. 
1.2.1.4 NADPH oxidase  
Superoxide generation by NADPH oxidase (NOX) was thought to only be present in 
"professional" phagocytes that promote microbial killing for a long time. Over the past years, 
six homologs of the cytochrome subunit of the phagocyte NADPH oxidase have been found 
(NOX1 to NOX5, DUOX1 and DUOX2) and they are now referred to as the NOX family of 
NADPH oxidases. These NOX enzymes are in fact found virtually in every tissue with the 
primary function of ROS generation [15]. NOX activation can be stimulated by a large group 
of stimuli, including toxic compounds, irradiation exposure, microorganism infection, growth 
factors and hormone activation.  Upon activation, NOX transports one electron at a time from 
NADPH to an oxygen molecule to generate superoxide and other downstream ROS, like 
hydrogen peroxide [16].   
1.2.1.5 Nitric oxide synthase 
There are three nitric oxide synthase (NOS) isoforms found in mammalian cells: neuronal 
NOS (NOS I) that is mainly expressed in neurons and are involved in synaptic functions in 
the central nervous system (CNS); inducible NOS (NOS II) that is expressed in many 
different cell types and is responsive to stimulation of cytokines, LPS (lipopolysaccharide) 
and other agents; endothelial NOS (NOS III) that is mainly expressed in endothelial cells and 
controls blood pressure. Monomeric forms of NOS have limited capacity to transfer electrons 
to molecular oxygen to generate superoxide. However, in presence of heme, NOS can form 
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functional dimers and transfer electrons from NADPH to O2 and L-arginine to form NO and 
L-citrulline [17] (see more details below).     
1.2.2 ROS formation and conversion  
When molecular oxygen is reduced by a single electron, it forms superoxide (O2.-), which is 
highly reactive and plays an important role in many signaling pathways such as activation of 
protein kinases and inactivation of phosphatases [18]. Superoxide is also quite toxic and used 
by phagocytes to kill invading microorganism [16].  !!   +   ! .!      !!.!     
Because superoxide is toxic, nearly all organisms that depend on aerobic respiration contain 
analogues of the superoxide-scavenging enzyme, superoxide dismutase (SOD). SOD 
catalyzes the conversion of superoxide to hydrogen peroxide (H2O2) [18]. Hydrogen peroxide 
is less reactive and involves in regulation of various physiological responses such as cell 
proliferation, differentiation, and migration. Hydrogen peroxide oxidizes and activates 
protein tyrosine kinases and at the same time, oxidizes and inactivates protein tyrosine 
phosphatases, which results in exaggerated phosphorylation signaling cascades.  This has led 
to implications of cellular “redox” signaling in regulating normal processes and disease 
progression [19].  2!! .!   +   2!!   !"#   !!!!   +   !!   
Hydrogen peroxide reacts with superoxide to generate the highly reactive and toxic hydroxyl 
radical, which is the Haber-Weiss reaction. This reaction is very slow and can be catalyzed by 
iron ions. The first step involves oxidation of superoxide to oxygen molecule by a ferric ion:  
                     (1)          !"!!   +   !! .!      !"!!   +   !!   
The second step is the Fenton reaction that involves the reduction of hydrogen peroxide to 
hydroxyl radical:  
              (2)          !"!!   +   !!!!      !"!!   +   !".   +   !"!   
Net reaction: 
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                                   !! .!   +   !!!!      !".   +   !"!   +   !! 
Hydroxyl radical (OH.) is by far the most reactive oxygen species with a half-life of about a 
nanosecond. It causes bases oxidation, thereby results in DNA mutation and carcinogenesis. 
Hydroxyl radical also readily targets the double bonds in polyunsaturated fatty acids to form 
lipid peroxides, which may induce apoptosis [20]. Further, tyrosine and tryptophan residues 
on proteins are additional targets to hydroxyl radicals, the oxidation of which may cause 
function alteration in protein and remodeling of cellular events [21].  
Nitric oxide (NO) is synthesized by converting L-arginine to L-citrulline, which is catalyzed 
by NOS. Most of the physiological effects of NO come from binding to guanylyl cyclase 
(GC)-coupled receptors, which results in conformational changes and generation of cGMP. 
This process affects multiple downstream targets including protein kinases, 
phosphodiesterases and ion channels. Nitric oxide can also modify proteins through post-
translation modification, such as the attachment of Nitric oxide to free a thiol group of the 
cysteine residue, named S-nitrosylation. This modification regulates the function of many 
proteins in cell signaling and can be reversed by several redox regulators [22].   
                    !"#   +   2!! +   !"#$%   +   !!   !"#   !"#   +   !"   +   2!!!   +   !"#$!   
Nitric oxide can also react with superoxide to form peroxynitrite (OONO-). Peroxynitrite is 
highly reactive and can directly react with DNA, proteins and lipids. However, these 
reactions happen at a relatively slow rate, which allows it to react more selectively in the cell. 
In addition, peroxynitrite can react with other molecules to form additional types of reactive 
nitro species, including nitrogen dioxide (.NO2) and dinitrogen trioxide (N2O3).                      !! .!   +   !"     !"!!!     
1.3  ANTIOXIDANTS 
Since high amounts of ROS result in oxidative stress and cellular damage, the mammalian 
cell have developed different antioxidant enzymes and utilizes low molecular weight 
compounds to prevent ROS toxicity and to keep redox homeostasis for the cellular events [7]. 
This section will give a brief introduction to these antioxidant enzymes with the focus on 
mammalian thioredoxin (Trx) system.   
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1.3.1 Selenium 
Jöns Jacob Berzelius (1779 - 1848), one of the first professors of Karolinska Institutet, is 
considered to be one of the founders of modern chemistry [23]. He had a great interest in 
mineralogy, which fostered his passion, knowledge and analytic skills for discovery new 
elements. In 1817, Berzelius found the pyrite created a red precipitate when working in the 
Falun mine, Sweden. It was first believed to be a tellurium compound. However, Berzelius 
doubted that since tellurium had never been found in the Falun mine. After scrutinizing and 
reanalyzing, Berzelius finally identified it as a newly found element with similar properties to 
sulfur and tellurium. Since tellurium is named after the latin name of earth, Tellus, Berzelius 
decided to name the new element "Selenium" for moon from the Greek word "selene" [24]. 
The naming was described in Swedish:. . . "skola beskrifvas vara en egen förut okänd 
brännbar mineralkropp, hvilken jag har kallat Selenium af ∑εληνη, måna, för at dermed 
utmerka dess nära slägtskap med Tellurium" [24]. 
Selenium is an essential trace element of fundamental importance to human biology. Humans 
take up selenium from diet. Meat, milk, eggs, seafood, cereal and nuts are selenium rich food 
[25, 26]. The antioxidant properties of nutrient selenium have received great attention. Most 
of its antioxidant activity is correlated with selenocysteine synthesis and incorporation into 
selenoproteins (see details below). However, another selenium-containing amino acid, 
selenomethionine, can scavenge ROS directly. Both free selenomethionine and 
selenomethionine residues in protein can rapidly react with peroxynitrite to form methionine 
selenoxide [27, 28], which can be reduced back to selenomethionine by glutathione in a non-
enzymatic reaction [29].  
Selenium deficiency has been linked to cardiovascular disease, reproductive impairment, 
inflammation and obesity [30, 31]. However, overdose of selenium becomes highly harmful 
to human health. It was reported that a commercial company provided a liquid dietary 
selenium supplement, which actually contained 200 times concentration as it labeled. This 
accident caused severe toxic effects to the users, such as diarrhea, fatigue, hair loss, joint 
pain, nausea and headache [32].  
1.3.2 Selenocysteine and Selenoproteins 
1.3.2.1 Selenocysteine in general 
A main biological role of selenium is to be used for selenocysteine (Sec, U) synthesis. Sec is 
the 21st naturally synthesized amino acid and an analogue to cysteine (Fig. 2) with a 
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selenium atom that replaces the sulfur in cysteine. This alteration gives Sec unique 
biochemical properties, such as lower pKa and higher nucleophilicity [33].  
 
Figure 2. Chemical structure comparison of Cys and Sec. 
1.3.2.2 Selenoprotein distribution 
Selenoproteins refers to proteins that contain at least one Sec, and they are present in all three 
major forms of life, archaea, bacteria and eukaryotes. Among bacteria and archaea, 
selenoproteins are not common and only found in certain phylogenetic groups [34]. In 
eukaryotes, selenoproteins are present in most animals with only a few identified in green 
alga Chlamydomonas, one in C. elegans, but completely missing from other plants or fungi 
[35, 36]. In recent years, through the development of bioinformatics and genomic analysis 
methods, the number of discovered selenoproteins has been rapidly expanded. So far, 25 and 
24 selenoproteins are identified in human and mouse, respectively [37], together with a few 
more found in bacteria and archaea [38]. Further, 310 different selenoprotein genes belonging 
to 25 families are found in samples collected from the Sargasso Sea [39] and more than 3600 
distinct selenoprotein genes derived from 58 selenoprotein families are identified in samples 
from the Global Ocean Sampling (GOS) expedition [40]. Nonetheless, selenoproteins seem to 
be dispensable for many organisms, such as plants, fungal and certain insects, which only 
use Cys-dependent homologue of the selenoproteins found in other species. It is apparent that 
Cys-dependent oxidoreductases are more common than their selenoprotein counterparts in 
nature [33]. All of these raise the question that what are the reasons for the existence of 
selenoproteins, and what unique properties can arise with selenocysteine in place of cysteine? 
1.3.2.3 Selenocysteine versus Cysteine 
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It is still an ongoing discussion why proteins use Sec instead of Cys. When comparing the 
chemical properties of selenium and sulfur, the two elements are very similar in terms of ion 
radii, redox potentials and electronegativity. However, selenium has lower pKa, higher 
polarizability and thus also higher nucleophilicity.  
The pKa difference between Sec and Cys (5.2 for the selenolate and 8.5 for the thiolate) is 
significant and often cited. Under physiological pH, most Cys molecules are likely to be in 
their protonated forms, which are less active. Sec, on the other hand, would mainly be 
deprotonated and more readily to be involved in chemical reactions. The low pKa also 
renders the selenolate become a superior leaving group relative to thiolate, which may 
accelerate the bond exchange between selenosulfide and disulfide in selenoproteins, such as 
mammalian thioredoxin reductase (TrxR) [41]. However, it is notable that these pKa values 
are only referred to free status of the amino acids, and the situation of Sec or Cys residues 
are highly dependently on the specific microenviroment of the protein structure [33]. For 
example, D. melanogaster has a-SCCS carboxyterminal active site motif in thioredoxin 
reductase (TrxR), instead of -GCUG as found in the mammalian orthologue. It is found that 
the activity of this non-selenorpotein TrxR is surprisingly high, due to the two flanking Ser 
residues that activate the two redox active Cys residues [42].  
Nucleophilicity refers to the capability to donate electrons to another atom or to supply a pair 
of electrons for the formation of a new bond with a foreign atom. Nucleophilicity consists of 
a combination of multiple factors such as atomic radius, pKa, polarizability and 
electronegativity. Significantly higher nucleophilicity of Sec as compared to Cys is believed 
to be the truly unique aspect of selenoproteins [33, 43]. A comparative study of the rate 
between selenol/diselenide and thiol/disulfide exchange reactions showed that at 
physiological pH, the higher nucleophilicity of selenium reacted more than 107 times faster 
than the corresponding sulfur compounds [44]. However, since the pKa of Sec is much lower 
than Cys as mentioned above, others argue that comparing activities under physiological 
conditions is in fact comparing the charged selenolate to a thiol (RSH). Therefore, the large 
difference in reaction rate betwen selenolate and thiolate can be mainly attributed to the 
concentration of nucleophilic species in the reaction [41]. Interestingly, an early study 
concluded that at very acidic pH, upon which Sec should be mainly in its protonated form 
still reacted readily with electrophiles due to the high nucleophilicity [45]. This inherent high 
nucleophilicity of Sec to efficiently react with electrophilic compounds may significantly 
contribute to its biological relevance. For example, it is attributing the high reactivity and 
broad substrate specificity of mammalian thioredoxin reductase (TrxR) to the high 
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nucleophilicity of the Sec residue in this enzyme [41].  The highly accessible Sec residue, 
which is easily targeted by a large number of electrophiles, may serve as an anticancer target 
[46]. It is also possible that in redox signaling pathways, the selenoproteins may catalyze the 
formation of intermediates using nucleophilic substitution reactions, where the Cys-
containing orthologues are unlikely to mimic such reactions efficiently even if having 
lowered pKa values [33].  
There is a new rationale for the requirement of Sec in proteins. It was noted that selenoprotein 
P, the only mammalian selenoprotein carries multiple Sec residues [47], evolved to appear 
when the amount of oxygen was increasing dramatically in the atmosphere [48]. It is 
paradoxical since it is well known that Se is much more susceptible to be oxidized to form 
selenenic (RSeOH) than S to form sulfenic (RSOH). However, further oxidation can occur on 
selenenic and sulfenic to form seleninic (RSeO2–) and sulfinic (RSO2–). The formation of 
Cys-SO2– in the protein is named "over-oxidation" [49], because it is extremely difficult be 
reduced back to a thiol, whereas Sec-SeO2– has the superior ability to be recycled back to 
selenol. One example in cellular context is that when Prxs are oxidized to form Cys-SO2–, 
they become inactivated and needs sulfiredoxin to restore their functions [50]. Further, it is 
showed that it is very difficult to further oxidize RSeO2– to RSeO3–, while RSO2– can be 
readily oxidized to RSO3–. In biochemical context, it means that Sec-SeO2– cannot be further 
oxidized to the selenonic acid (Sec-SeO3–), while Cys-SO2– can be oxidized to the sulfonic 
acid (Cys-SO3–), which is referred to as "hyper-oxidation". There is no known pathways or 
enzymes of reducing Cys-SO3– to thiol in biological systems. Thus, Sec will be favored by 
those proteins, which are needed to be highly resistant to irreversible oxidation and 
inactivation [48].  
1.3.2.4 Selenocysteine synthesis and incorporation in eukaryotes  
The biosynthesis of Sec in eukaryotes is initiated by aminoacylation of the tRNA that 
carrying Sec (tRNA[Ser]Sec) with serine (Ser). This reaction is catalyzed by seryl-tRNA[Ser]Sec 
synthetase (SerS), and then the tRNA[Ser]Sec with serine moiety is converted to phosphoseryl-
tRNA[Ser]Sec by phosphoseryl-tRNA[Ser]Sec kinase (PSTK). Under selenium sufficient condition, 
selenophosphate (SePO3) will be synthesized by selenophosphate synthesase 2 (SPS2), which 
will be used as the selenium donor for converting phosphoseryl-tRNA[Ser]Sec to Sec-
tRNA[Ser]Sec by selenocysteine synthase (SecS) [51]. However, it shows that upon selenium 
deficient condition, SPS2 would provide thiophosphate (SPO3) instead of SePO3 to SecS for 
synthesis of Cys instead of Sec onto the tRNA[Ser]Sec (Fig. 3). As a result, selenium deficient 
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condition promotes Cys incoporation into the site of Sec residue in selenoproteins in mice [52, 
53].  
 
Figure 3. Biosynthesis of Sec and de novo synthesis of Cys. SerS and PSTK catalyzes 
successively to convert tRNA[Ser]Sec to phosphoseryl-tRNA[Ser]Sec. SPSP2 utilizes selenide or 
sulfide as the substrates to produce SePO3 or SPO3, which is thereafter utilized by SecS to 
convert the phosphoseryl-tRNA[Ser]Sec intermediate to either Sec-tRNA[Ser]Sec or Cys-
tRNA[Ser]Sec. The figure is modified from Turanov et al. [51].   
Selenoprotein synthesis utilizes a unique and complex machinery to incorporate Sec into in-
frame UGA codon, which is normally a stop codon that terminates the translation [54]. Sec 
incorporation sequence (SECIS) is a secondary structure of mRNA that forms stem loop 
sharp, which plays an essential role for Sec incorporation in UGA codon [37]. When the 
ribosome encounters the in-frame UGA codon in mRNA of a selenorprotein, Sec-tRNA[Ser]Sec 
with a anticodon UCA translates UGA as Sec under the coordination of SECIS element [55]. 
SECIS binding protein 2 (SBP2) is well known to bind SECIS element with high specificity 
and affinity to recruit Sec-tRNA[Ser]Sec and facilitates the incorporation of Sec into the 
synthesized peptide [56]. Sec-specific translation elongation factor (EFSec) is another 
important player in eukaryotic Sec incorporation machinery, which forms complex with 
SBP2 and thereafter facilitates the interaction with SECLIS element and Sec encoding [57].   
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Ribosomal protein L30 is a component of large ribosomal subunit in eukaryotes, which has 
also been shown to bind SECIS element. Studies have revealed that L30 binds equally well to 
open and kinked SECIS elements, whereas SBP2 preferentially binds to open form of SECIS 
structures [58]. However, the exact role of L30 in Sec incorporation is yet unclear and needs 
further investigation. Nucleolin is found to be another SECIS element binding protein that 
influences the translation efficiency of UGA into Sec, whereas there is no consensus on the 
role of nucleolin in regulation of Sec incorporation. One study shows that nucleolin 
preferencially bind SECIS elements in the high ranked selenoproteins in the hierarchy of 
selenoprotein expression, but can hardly bind the SECIS elements from nonessential 
selenoproteins [59]. Another study with conflicting data shows that necleolin bind SECIS 
elements in variety of selenoproteins without major differences [60]. A eukaryotic translation 
initiation factor eIF4a3 has been shown to be an important regulator of Sec incorporation, 
which contributes to the preferential translation of the high ranked selenoproteins in the 
hierarchy of selenoprotein expression [61]. It has been shown that eIF4a3 is dramatically 
induced under Se deficient condition, which is proposed to selectively bind SECIS elements 
in the nonessential selenoproteins mRNA to compete with the binding of SBP2 and results in 
prevention of Sec incorporation into the nonessential selenoproteins [62]. Take into 
consideration that multiple proteins can bind SECIS elements, including SBP2, L30, 
nucleolin, eIF4a3, and possibly more, it is plausible that these regulations act in concert to 
regulate the expression of selenoproteins (Fig. 4). Additional studies are needed to investigate 
the exact mechanism of different proteins that bind SECIS element in regulation of 
selenoprotein synthesis and dictation of the hierarchy of selenoprotein expression.  
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Figure 4. Sec incorporation into selenoproteins in eukaryotes. SBP2 and EFSec formed 
complex binds the stem loop like SCEIS element and facilitate the Sec incorporation at in-
frame UGA codon decoded by tRNA[Ser]Sec. L30, nucleolin and eIF4a4 are involved in the 
regulation of Sec incorporation. The figure is modified from Vyacheslav et al. [54].    
1.3.3 Trx system 
1.3.3.1 Trx system in general 
The thioredoxin (Trx) system consists of Trx, thioredoxin reductase (TrxR) and the cofactor 
NADPH. Mammalian TrxR are selenoproteins having a Sec in the C-terminal -GCUG motif. 
TrxR uses reducing equivalents from NADPH to reduce oxidized Trx and thus supports a 
range of Trx-dependent cellular functions, including cell proliferation, redox regulation and 
antioxidant defense [46, 63].   
1.3.3.2 Trx isoforms 
Trx is a small (approx. 12 kDa) disulfide reductase universally expressed in all living cells 
[64]. There are two major isoforms of Trx in mammals. Trx1 is predominately located in 
cytosol and nucleus. However, Trx1 and its truncated form Trx80 have also been found in the 
membrane and extracellular space. Trx2 is specifically located in the mitochondria. The 
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active site of Trx contains two cysteine residues with the sequence of -Cys-Gly-Pro-Cys- 
[65]. Active site oxidized Trx is reduced to dithiol by NADPH and TrxR, and GSH together 
with glutaredoxin may serve as a backup system for Trx reduction [66]. Genetic depletion of 
both Txn and Txn2 that encodes Trx1 and Trx2 respectively, gave early embryonic lethality in 
mice [67, 68].   
1.3.3.3 TrxR isoforms  
There are three isoforms of TrxR in both human and mouse. TrxR1 is the major form of TrxR 
that locates mainly in cytosol and expresses in most tissues (See more details below). TrxR2 
is predominantly located in mitochondria with much lower levels than TrxR1 in most tissues. 
Together with the mitochondrial version of thioredoxin (Trx2), TrxR2 is involved in 
antioxidant defense against ROS generated from mitochondrial electron transport chain [69]. 
TrxR2 has also been shown to be essential for hematopoiesis and heart development [70]. 
The transcription of the genes encoding TrxR1 and TrxR2 involve different splicing variants 
at the N-terminal end, resulting in different protein variants [46]. Another isoform of TrxR is 
thioredoxin glutathione reductase (TGR), which consists of a TrxR module with a N-terminal 
elongation containing an atypical monothiol -CPHS- motif in a glutaredoxin domain [71]. 
TGR is found to be present at very low levels in various tissues but the levels of TGR 
increases in testis after puberty. This enzyme is absent from mature sperm but is highly 
enriched in elongating spermatids at the site of mitochondrial sheath formation, which 
indicates unique functions of TGR in relation to spermatogenesis [71].  
1.3.3.4 Catalytic mechanism of Mammalian TrxR1  
Mammalian TrxR1 is a homodimer arranged head-to-tail with a Sec in its C-terminal -GCUG 
motif in each subunit (Fig. 5). Both subunits are required for electron transfer in the reduction 
reaction from NADPH to Trx. In the initiation of the reaction, the FAD bond with each 
subunit obtains the electrons from NADPH and thereafter transfers them to the -CVNVGC- 
motif of the same subunit in N-terminal and thus forming a dithiol motif. The dithiol-
containing motif in one subunit of TrxR1 reduces the selenenylsufide motif in the other 
subunit of the dimer. The reduced C-terminal active site with a selenothiol motif 
subsequently reduce a broad number of substrates in cells including the active site disulfide 
of Trx (Fig. 5). However, some substrates such as certain quinones and 5,5'-dithiobis-(2-
nitrobenzoicacid) (DTNB), may be reduced directly by N-terminal -CVNVGC- active site 
[72].  
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Figure 5. The catalytic mechanism of Mammalian TrxR1. During catalytic reaction, 
NADPH transfers electrons to enyme-bound FAD, which thereafter reduces the disulfide 
bond in the N-terminal -CVNVGC- motif. The reduced N-terminal sebsequently reduce the 
selenenylsufide-containing motif in the C-terminal of the other subunit. The formed 
selenothiol motif can reduce a broad range of substrates, including active site disulfide of Trx, 
other protein disulfide substrates, as well as non-protein substrates such as selenium 
compounds, peroxide, DTNB, lipoic acid and etc.    
1.3.3.5 Cellular functions and substrates of mammalian TrxR1 and Trx1  
The main physiological substrate of TrxR1 is Trx1. Reduced Trx1 is the reducing equivalent 
donor for many enzymes and proteins. Through reduction of Trx1, TrxR1 exert many 
important cellular functions, such as the reduction of ribonucleotide reductase (RNR), which 
is essential for DNA synthesis and cell proliferations [63]. TrxR1 also supports a range of 
antioxidant enzymes through Trx1, including peroxiredoxins (Prxs) and methionine sulfoxide 
reductases (Msrs). Prxs catalyze the scavenging of H2O2 with a high affinity to prevent 
oxidative stress and modulate signaling cascades [49]. Msrs recycle methionine sulfoxide 
back to methionine to repair oxidative damage on methionine residues of proteins [73].  
In addition to supporting different enzymes, TrxR1 is also involved in regulation of cellular 
signaling transduction through altering activities of transcription factors, kinases and 
phosphatases. Via Trx1 reduction, TrxR1 either directly supports NF-κB through reducing its 
Cys residues [74, 75] or indirectly sustains HIF1a and AP1 via redox factor-1 APE/Ref-1 [76, 
77]. Reduced Trx1 can non-covalently interact with apoptosis signaling-regulating kinase 1 
(ASK1) and inhibit apoptosis signaling [78]. Recently, Trx system is shown to reduce and 
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reactivate oxidized protein-tyrosine phosphatase 1B (PTP1B), thereafter negatively regulate 
Platelet-derived growth factor β (PDGF-β) receptor tyrosine kinase signaling and potentially 
also suppress insulin signaling [79]. Likewise, reduced Trx1 may reduce oxidized 
phosphatase and tensin homolog (PTEN) and inhibit PI3K/Akt pathway [80]. However, 
conflicting data shows that Trx1 in reduced form can covalently interact with PTEN and 
inhibit PTEN activity, thereby augmenting PI3K/Akt signaling [81].  
Further, through reduction of Trx1 or thioredoxin-related protein of 14 kDa (TRP14), TrxR1 
catalyzes efficient cystine reduction reactions, which might be an essential source of cysteine 
that is required for protein synthesis and cellular redox homeostasis [82, 83]. TrxR1 also 
plays a role in denitrosylation of S-nitrosylated glutathione, caspase 3 or cathepsin B through 
either Trx1- or TRP14-catalyzed denitrosylation reactions [82]. Additional protein substrates 
to TrxR1 are glutaredoxin 2 which is predominant in mitochondrial and protein disulfide 
isomerase (PDI) in ER, more studies are required to understand how these reaction occurs 
[84, 85]. 
p53 is a redox sensitive transcription factor that plays an essential role in DNA repair, cell 
cycle arrest and apoptosis [86]. TrxR1 is reported to be required for p53 functions. Depletion 
of gene trr1 that encodes TrxR1 in yeast dramatically decreases p53 activity but not p53 
protein level [87, 88]. Electrophilic prostaglandins are shown to covalently modify and 
inhibit TrxR, which results in impairment of conformation and function of p53 [89, 90]. 
TrxR1 also indirectly facilitates DNA binding activity of p53 through redox regulation of Trx 
and APE/Ref-1 [91, 92]. 
TrxR1 also has additional non-proteins substrates in cells. It can reduce different forms of 
selenium compounds. Reduction of selenite to selenide consumes NADPH and triggers a 
redox cycling process in the cells, which might contribute to the prooxidant and lethal effects 
of high selenite concentrations [93]. TrxR1 is also known to be able to regenerate Vitamin C 
through reduction of dehydroascorbate to asorbate [94], which may be part of the total 
antioxidant activity of TrxR1. Ubiquinone is shown to be another endogenous substrate for 
both purified and cellular TrxR1. It is not yet known the biological importance of this 
reduction, but it indicates that selenium and ubiquinone may protect the cells from oxidative 
damage in a combinatory manner [95].   
1.3.3.6 TrxR1 knockdown or knockout  
Two independent studies observed that deletion of Txnrd1 (gene encodes TrxR1 in mouse) 
results in early embryonic lethality [96, 97]. The earlier study shows that embryonic death 
occurs between embryonic day E9.5 and E10.5 with normal gastrulation and mesoderm 
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formation [96]. However, the latter study reports that Txnrd1 null embryos are viable at 
embryonic day E8.5 but not at E9.5 with failure of gastrulation and mesoderm formation 
[97]. Even though the time points for the death of the Txnrd1 null embryos are slightly 
different between the studies, it actually imposes a major difference in terms of the functional 
impact of depletion of Txnrd1. The molecular mechanism for this difference is still unknown. 
Notably, although these knockouts are embryonically lethal, the lethality occurs after several 
rounds of cell division and forms thousands of cells, showing that TxrR1 is not essential for 
cell proliferation but vital for certain signaling events that are required for embryonic 
development. Nervous system (NS)-specific deletion Txnrd1 results in development of 
massive cerebellar hypoplasia, which indicates that TrxR1 is important for postnatal brain 
development [98]. Under serum starvation, attenuation of TrxR1 in a k-ras driven mouse 
cancer cell line causes a loss of self-sufficiency of growth [99]. TrxR1 knockdown in a 
mouse lung cancer cell line also leads to a reversal in morphology and anchorage-
independent growth features, completely abrogating the ability to form tumors in a xenograft 
model system [100]. Recently, depletion of Txnrd1 is shown to affect cellular signaling and 
nutrient metabolism. Upon serum starvation condition, protein tyrosine phosphatase 1B 
(PTP1B) is more oxidized in TrxR1-defiecent mouse embryonic fibroblasts (MEFs), which 
results in augmented platelet-derived growth factor (PDGF) stimulated response [79]. 
Hepatocyte-specific disruption of Txnrd1 is shown in one study to repress lipogenesis and 
increase glycogen storage dramatically in liver [101], while another study reports hepatic 
lipidosis with liver-specific TrxR1 knockout [102]. 
Interesting, tissue- or cell- specific suppression of TrxR1 does not necessarily give apparent 
phenotype. Conditional heart-specific Txnrd1 deletion does not affect Cardiac development 
and cardiomyocytes derived from knockout embryos with Txnrd1-deficiency survive and 
grow in vitro [96]. Neuron-specific removal of Txnrd1 does not cause any disorder in brain 
development [98]. Likewise, hepatocytes lacking TrxR1 proliferate normally during 
development and regeneration in mice without exhibiting apparent phenotype [103]. In 
cellular systems, downregulation of TrxR1 neither induces oxidative stress nor causes Trx1 
oxidation in HeLa cells [104]. Knocking down TrxR1 with approx. 90% efficiency gives no 
effect on A549 cells [105]. It also shows that depletion of Txnrd1 lacks apparent phenotype 
on c-myc and H-ras driven transformed cells with similar proliferative, clonogenic and 
tumorigenic capability [106]. Txnrd1 is further found to be dispensable for c-myc driven B-
cell lymphomagenesis, however, the survival and growth of this tumor is strictly dependent 
on the present of sufficient GSH, suggesting that the antioxidant defense and DNA synthesis 
in Txnrd1 deficiency cells is compensated by upregulation of GSH-dependent system [106]. 
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1.3.3.7 TrxR1 as an anticancer target 
As discussed above, the Sec-containing C-terminal of mammalian TrxR1 is highly 
nucleophilic and serves as an easily accessible target for electrophiles [33]. Intriguingly, 
many studies observe that targeting TrxR1 gives more potent cytotoxicity and cell death than 
that caused by TrxR1 knockdown or knockout. It is plausible that the electrophiles have 
many other targets in the cells addition to TrxR1, but genetic depletion or transcription 
suppression specifically affects the expression of TrxR1. However, it shows that TrxR1 with 
Sec truncation or compromised by reaction with electrophiles such as cisplatin, results in gain 
of a pro-oxidant function that induces ROS production and extensive cell death [107, 108]. 
The pro-oxidant forms of TrxR1 are termed SecTRAPs, referring to selenium-compromised 
thioredoxin reductase-derived apoptotic proteins). Further studies show that an intact FAD/N-
terminal motif in the SecTRAPs is required for the pro-oxidant and cell-killing activity, 
suggesting that N-terminal dependent NADPH consumption and redox cycling is responsible 
for the ROS production of SecTRAPs [108].  
Cisplatin was approved for clinical use of cancer therapy in 1970s [109]. It has been known 
for long time that the success of cisplain in chemotherapy derives from its DNA crosslinking 
ability, which causes DNA damage and cell death [110, 111]. However, targeting TrxR1 and 
inducing SecTRAPs formation have also been indicated to contribute significantly to the 
reaction mechanism of cisplatin [105, 112]. Downregulation of TrxR1 to approx. 10% causes 
no apparent phenotype in A549 cells, but increases the resistance to cisplatin dramatically 
[105]. A p53 activator anticancer drug lead RITA have also been shown to target TrxR1 and 
cause a p53 dependent ROS generation, which may synergize with p53-dependent induction 
of apoptosis thus resulting in a robust cancer cell death [113]. Arsenic trioxide (ATO) has 
been used as a drug for thousands of years in traditional medicine [114] and has been used 
recently to treat acute promyelocytic leukemia (APL) [115, 116].  It shows that ATO targets 
Sec on TrxR1 and irreversibly inhibits the enzyme activity, which subsequently leads to 
oxidative stress and Trx oxidation. This indicates that targeting TrxR1 might contribute to the 
anticancer acticity of ATO [117]. The Gold compound auranofin, a clinically approved drug 
to treat rheumatoid arthritis, is also found to be potent inhibitor of TrxR1. Targeting TrxR1 
by auranofin induces apoptosis in cisplain-resistant human ovarian cancer cells, adramycin-
resistant human leukemia cells and human lung adenocarcinoma epithelial cells [112, 118, 
119]. Clinical studies evaluating the possibility to use auranofin as an anticancer drug against 
different cancer types are in progress [120, 121].  
Xiaoxiao Peng 
 20 
Targeting TrxR1 seems to be much more toxic to cancer cells than healthy tissues, which 
make it become an intriguing anticancer strategy. Many studies show that cancer cells have 
increased ROS levels compared to their normal counterparts [122, 123]. In order to adapt to 
the increased oxidative stress, the cancer cells utilize enhanced antioxidant systems to 
counteract ROS generation and balance redox hemostasis. The activation of antioxidant 
responsive transcription factor Nrf2 (nuclear erythroid 2-related factor 2), which regulates the 
expression of multiple enzymes involved in antioxidant defense, is an important mechanism 
for this adaptation [124-127]. However, the accumulated ROS levels in cancer cells are close 
to reach the threshold that triggers cell death. Cancer cells are thus highly dependent on 
cellular antioxidant systems. Compounds that disrupt the antioxidant capacity in cells might 
elevate the ROS further to reach beyond the threshold and causes extensive cell death [128]. 
This may explain why targeting TrxR1 has been shown to induce cell death in many cancer 
cells [129-131]. On the other hand, under physiological conditions, normal cells contain a 
low level of ROS by balancing the ROS generation and antioxidant capacity. A certain level 
of ROS elevation is tolerable to normal cells due to their responsive antioxidant capacity 
[128]. TrxR1 inhibition could even be protective to normal tissues: TrxR1 inhibitor 
aurothioglucose (ATG) is shown to attenuate lung injury caused by hyperoxic condition due 
to the protective effects from augmentation of GSH system [132, 133]. Mice with Txnrd1-
null hepatocytes are more resistant to paracetamol induced liver damage, due to the more 
robust GSH systems promoted by Nrf2 activation [101]. Thus, targeting TrxR1 by compound 
inhibition may specifically kill cancer cells and keep normal cells intact, which may serve as 
an intriguing anticancer strategy and further investigation is needed.   
1.3.3.8 Txnip 
An important cellular regulator of Trx is thioredoxin-interacting protein (Txnip also named 
VDUP1 or TBP2). Txnip forms a disulfide bond via Cys247 with Trx catalytic Cys32 to 
inhibit Trx activity and function [134, 135], thereby playing an essential role in redox 
signaling in a Trx-dependent manner. It shows that Txnip is able to dissociate Trx from 
ASK1, thus activating ASK1-JNK (c-jun-N-terminal kinase) signal pathway in inflammatory 
response [136]. In addition, hyperglycemia induces expression of Txnip through activation of 
p38 MAPK pathway and carbohydrate response element in Txnip promoter, and promotes 
ROS generation by inhibiting Trx activity, inducing mitochondrial and Nox4 ROS [135, 
137].   
However, being one member of arrestin protein family, Txnip has many other Trx 
independent cellular functions [138]. Studies show that Txnip inhibits adipogenesis 
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independent of its bind to Trx, however the interaction with Trx is required for the 
stabilization of Txnip from proteasomal degradation [139]. High concentrations of ROS 
promote the dissociation between Txnip and Trx, which indicates that the metabolic function 
of Txnip is redox regulated through Trx dependent stability control [134]. A very important 
role for Txnip has been proposed in the glucose homeostasis regulation. Txnip deficiency 
enhances insulin sensitivity with activated Akt signaling and glucose uptake [140-142]. 
Downregulation of Txnip restores glucose stimulated insulin secretion, attenuated beta cell 
apoptosis and ROS generation [143]. Further, Txnip null hepatocytes show reduced 
gluconeogenesis [144]. Taken together, it appears that Txnip is a very promising therapeutic 
target for type 2 diabetes. Another important role of Txnip is acting as a tumor suppressor. 
Nucleus translocation of Txnip increases the levels of cyclin dependent kinase (CDK) 
inhibitor p27 and p16, thus causes G1 cell growth arrest and suppresses tumor growth [145-
147].      
1.3.3.9 Prxs 
Six different types of mammalian peroxiredoxins (Prxs) have been found, which are divided 
into three types, 2-Cys, atypical 2-Cys and 1-Cys subgroups. Prx I-IV belong to 2-Cys 
subgroups, whereas Prx V and Prx VI are members of atypical 2-Cys and 1-Cys subgoup 
respectively. Prxs are distributed in different cellular compartments: Prx I and II are in the 
cytosol, Prx III locates in the mitochondria, Prx IV is found in ER as well as in the 
extracellular space, Prx V is expressed in mitochondria and peroxisomes, and Prx VI locates 
in cytosol. All Prxs are homodimers and contains a conserved Cys at the N-terminal motif, 
which is the primary H2O2 reducing site. Prxs all need Trx as a source of reducing equivalents 
for their peroxidase activity [148]. The Vmax of Prx I-III is 6-13 µmol/min-1mg-1 at 37oC, 
relatively slower than catalase and Gpx [149]. However, since they have higher affinity 
towards H2O2 (Km values for H2O2 are < 20 µM) and are abundant in most cells, Prxs can be 
very efficient in removing lower levels of H2O2 in the cells [148]. In addition to protect the 
cells from oxidative damage, Prxs are also involved in regulation of H2O2 mediated signaling 
cascades. Overexpression of Prx I and II in cultured cells eliminate growth factor induced 
ROS production. Overexpression of Prx II inhibites tumor necrosis factor-α (TNFα) induced 
nuclear factor κB (NFκB) activation [150]. Moreover, mouse Prx-IV overexpression reduces 
the epidermal growth facor or p53 induced ROS significantly [151]. Taken together, these 
findings suggest that Prxs regulate intracellular redox signaling through control of cellular 
ROS.   
Xiaoxiao Peng 
 22 
1.3.4 GSH system 
In addition to Trx system, another important NADPH dependent antioxidant system is the 
glutathione (GSH) system. GSH plays an essential role in this system and serves as an 
electron donor for glutaredoxin (Grx) and gluathione peroxidase (Gpx). Glutathione is also 
used by gluathione transferase (GST) conjugating the xenobiotic substrates [152, 153]. In 
mammalian cells, the GSH concentration is from 0.5 - 10 mM. Most GSH (approx. 90%) is 
in cytosol, whereas the rest is found in mitochondria, peroxisomes, ER and nuclear [154, 
155]. GSH is readily oxidized to glutathione disulfide (GSSG) through reaction with ROS 
[152]. GR receives reducing equivalents from NADPH to reduce GSSG back to GSH, and to 
keep the GSH : GSSG ratio in a physiological range, normally > 10 [152]. Interesting, 
genetically GR deficient are viable [156], and the mice hepatocytes with germline GR 
knockout showed a normal total GSH level and GSH : GSSG ratio [157]. This could be 
explained by the fact that the major source of reduced GSH in the cells is from GSH 
synthesis, but not the GSSG reduction through GR.   
1.3.4.1 GSH synthesis 
The synthesis of GSH from L-glutamate, L-cysteine and glycine is catalyzed in two 
consecutive steps by γ-glutamyl-cystien ligase (GCL) and GSH synthase  [152, 153]. The 
formation of the dipeptide γ-glutamylcysteine (γ-GC) is the rate-limiting step in the synthesis 
of GSH catalyzed by GCS, which involves ATP-dependent condensation of L-glutamate and 
L-cysteine [158]. GCL is holoenzyme consists of a 73 kDa catalytic heavy subunit (GCLC) 
and a 31 kDa regulatory light subunit (GCLM), which are encoded by separate genes. It 
shows that GCLC exhibits catalytic activity and feedback inhibited by GSH, whereas GCLM 
has no enzymatic activity [159, 160]. Mice with embryonic homozygous knockout of the 
catalytic heavy subunit GCLC fail to gastrulate with no mesoderm formed and died before 
E8.5. However, cells isolated from the GCLC-/- blastocysts proliferate normally in vitro 
[161]. On the other hand, genetically disrupt the regulatory light subunit GCLM results in 
viable and fertile mice with decreased total GSH levels in multiple organs. GCLC with 
genetic absence of GCLM has approx. 2-fold increase in Km for glutamate and significantly 
increased sensitivity to GSH inhibition. The Gclm deficient fetal fibroblasts show enhanced 
susceptibility to oxidant such as H2O2 [162]. 
1.3.4.2 Grx 
Glutaredoxins (Grxs) belong to the Trx fold family and were first described as glutathione-
dependent reductases for the disulfide bond formed in RNR. They are four forms of Grxs in 
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human cells. Grx1 and Grx2 are major forms of Grxs with dithiol motif; however, Grx3 and 
Grx5 are monothiol Grxs.  Grx1 is a cytosolic protein with the active site Cys-Pro-Tyr-Cys. 
Grx2 locates in mitochondria and contains the active site Cys-Ser-Tyr-Cys. During catalytic 
reaction, active site oxidized dithiol Grxs are reduced and reactivated by two GSH molecules, 
thereafter forming reduced Grxs and one molecule of GSSG. Reduced Grxs serve as general 
disulfide oxidoreductases and regulate the activity of redox sensitive transcription factor and 
phosphatase [163-165]. In addition to dithiol mechanism, another important function of Grxs 
is the monothiol reduction mechanism. S-glutathionylation is an important post-translation 
modification on proteins in redox signaling, which protects the cysteine from irreversible 
oxidation and is increased during oxidative stress. Most of the deglutathionylation in 
mammalian cells are carried out by Grxs monothiol reduction [166].        
1.3.4.3 Gpx 
Glutathione peroxidases (Gpxs) are well-known antioxidant enzymes scavenging H2O2 or 
organic hydroperoxides, typically using GSH as the source of reductant [25, 167]. They are 
eight Gpx isoforms found in mammals: mammalian Gpx 1-4 are selenoproteins with a Sec in 
the catalytic motif, and Gpx6 contains Sec in human but expresses as a Cys-containing 
counterpart in mice and rat. Gpx5, 7 and 8 are, however, Cys-containing enzymes in 
mammals [167]. Gpx1 is the first described selenoprotein and ubiquitously expresses in 
cytosol and mitochondria [168-170]. Gpx1 is involved in redox regulation of insulin 
signaling. Gpx1 overexpression causes insulin resistance due to over removal of H2O2, which 
serves as a signaling molecule for insulin signaling transduction [171, 172]. Gpx2 is mainly 
found in gastrointestinal systems and therefore, also named GI-Gpx [167].  Gpx2 plays a dual 
role in carcinogenesis: on one side, it prevents oxidative stress induced DNA damage and 
suppresses malignant initiation; on the other side, Gpx2 is overexpressed in many type of 
cancers to support antioxidant defense and cancer cell survival [167, 173]. Gpx3 is mainly 
present in the proximal convoluted tubule of the kidney and plasma. In addition to ROS 
scavenge, Gpx3 prevents hydroperoxide-mediated activation of lipoxygenases, and thus, 
suppressing inflammatory responses [174, 175]. Gpx4 is also ubiquitously expressed in 
cytosol and mitochondria [167]. Specific mitochondrial Gpx4 knockout results in 
spermatozoa maturation abnormality [176, 177]; however, systematic knockout of Gpx4 is 
embryonically lethal [178]. Evidence suggests that GPx4 possess a crucial protective function 
in neuron system by controlling the lipid hydroperoxides level [179]. Gpx5 predominantly 
expresses in epididymis and is crucial for protecting the spermatozoa from oxidative damages 
[180]. The knowledge of the function of Gpx6-8 is limited. Gpx6 is found in olfactory system 
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and may be involved in hearing. Gpx7 and Gpx8 are ER proteins and hypothesized to be 
important for protein folding [167].   
1.3.4.4 GST 
Glutathione transferases are also named Glutathione S-transferases (GSTs), which comprise a 
family of phase II detoxification enzymes. GSTs are divided into three major families of 
proteins, the cytosolic and mitochondrial GST, as well as the microsomal GST. GSTs are 
well known for catalyzing the nucleophilic conjugation of the reduced GSH to electrophilic 
carbon, sulfur, or nitrogen atoms of nonpolar xenobiotic substrates, thus preventing their 
interaction with crucial cellular components. These substrates contain quinones, 
nitrobenzenes, arene oxides, and α, β-unsaturated carbonyls [181]. In most cases, GSH 
conjugation on the xenobiotic substrates leads to formation of less reactive compounds, 
which are subsequently secreted from the cells. However, in certain cases, the GSH 
conjugated compounds are more reactive than the parent molecule. For instance, GSTs 
catalyze the conjugation of 1,2-dihaloethanes with GSH, which leads to the formation of 
genotoxic GSH conjugates with an episulfonium intermediate that can modify DNA [182]. 
This feature of GSTs has been utilized in cancer chemotherapy to produce reactive 
metabolites that can target tumor cells with an upregulated expression of transferases [181]. 
One example is the cytotoxic drug TER286 (also called TLK286) is activated by GST to 
produce a nitrogen mustard-alkylating agent, which is cytotoxic to murine xenografts [183].  
1.3.5 Trx and GSH maintained cytosolic redox homeostasis 
The NADPH dependent Trx and GSH systems work together to maintain cytosolic redox 
homeostasis, DNA replication, ROS scavenge, and cystine reduction in mammalian cells. 
However, a recent study shows that mammalian hepatocytes have a third, NADPH-
independent pathway that can support cytosolic redox homeostasis in the absence of TrxR1 
and GR. It demonstrates that this pathway utilizes methionine-fueled trans-sulfuration (MTS) 
to supply necessary cysteine for GSH and protein sysnthesis, which can therefore maintain 
cytosolic redox homeostasis and cell growth independent of NADPH [157] (Fig. 6).  
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Figure 6. Trx and GSH maintained cytosolic redox homeostasis. Mammalian cells take up 
glucose through glucose transport (GLUT), and then hexokinases convert glucose to glucose-
6-phosphate (G6P). G6P undergoes pentose phosphate pathway through the catalytic reaction 
of glucose-6-phosphate dehydrogenase (G6PD) and generates NADPH. TrxR1 and GR 
receive reducing equivalents from NADPH to reduce oxidized Trx1 or oxidized GSH 
(GSSG) respectively, thereby supporting redox homeostasis, ROS scavenging, and RNR 
reducing. xCT transporter on the membrane imports cystine from extracellular environment 
and exports glutamate. Cystine is reduced to cysteine (Cys) for GSH synthesis by either the 
Trx/TRP14 or the GSH system. Methionine can also maintain cytosolic redox homeostasis 
through MTS pathways to produce Cys, which is then used for GSH and protein synthesis.   
1.3.6 Other antioxidant enzymes 
Superoxide is produced by a single electron reduction of an oxygen molecule and causes 
many types of oxidative damages (see section 1.2.2). To be protective, superoxide dismutases 
(SODs) are ubiquitously expressed and catalyzes the dismutation of superoxide (O2.-) to 
hydrogen peroxide (H2O2), which is less reactive and can be degraded by other enzymes, 
such as Prxs, Gpxs or catalase (see below). There are three forms of SODs present in humans. 
SOD1 or CuZn-SOD is a copper and zinc-containing homodimer and is found almost 
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exclusively in the cytosol. SOD2 or Mn-SOD is a maganeses-containing tetramer and is 
exclusively located in the mitochondrial matrix. SOD3 is a recently characterized tetramer 
enzyme, with copper and zinc in its active center and present extracellularly [184].  
Catalase is widely distributed to bacteria, fungi, plants and animals that exposed to oxygen 
[185]. Catalases are divided into three types: typical or mono-functional catalases, 
bifunctional catalase-peroxidases, and pseudo catalase. The mammalian catalase is a 
homotetramer mono-functional catalase with molecular weight of each subunit approx. 60 
kDa. Each subunit contains a heme, ferriprotoporphyrin IX group in its active center [186]. 
This heme-containing protein is the most efficient enzyme, that can degrade millions of 
hydrogen peroxide molecules every second (~107 per sec) into molecular oxygen and water 
[187].  
1.3.7 Low molecular weight antioxidants 
In addition to enzyme dependent antioxidant defense system, low molecular weight 
antioxidants are also important to humans, especially to blood and other biological fluids, 
where antioxidant enzyme systems are deficient or even absent. Vitamin A consist of a group 
of unsaturated hydrocarbons, including retinol, retinal, retinoic acid and several provitamin A 
carotenoids [188]. Vitamin A is able to directly quench singlet oxygen [189-191], it also 
inhibits NO production through inhibition of iNOS gene transcription [192]. Vitamin C 
(ascorbate) is the most important water-soluble low molecular weight antioxidant. It directly 
scavenges different type of ROS, especially O2.- and OONO- [193]. Vitamin E is the mixture 
of different isoforms of tocopherol and tocotrienol, among which α-tocopherol is the most 
biological form. Vitamin E is the major lipid-soluble antioxidant and plays an essential role in 
protecting the cellular membrane from lipid peroxidation [191, 194, 195]. Tocopheroxyl free 
radical can be recycled back to α-tocopherol by ascorbate, thus acting together to prevent 
lipid peroxidation [196]. Oxidized ascorbate can be recycled back to reduced form through 
either the Trx or the GSH system [7].  In addition to its enzymatic related reactions discussion 
above (see section 1.3.4), GSH itself directly reacts with lipid peroxyl radical, peroxynitrite 
and H2O2. Further, GSH conjugates with NO, forming S-nitroso-glutathione adduct [152]. α-
Lipoic acid (LA) is also an important antioxidant. The reduced form of Lipoate, 
dihydrolipoate, can react with various forms of ROS. It also protects cell membranes from 
oxidative damage by interacting with vitamin C and GSH, which may in turn recycle vitamin 
E [197].  
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1.4 HIGH GLUCOSE AND OXIDATIVE STRESS  
High glucose circumstance has been shown to induce oxidative stress and hyperglycemia 
induced oxidative damage has been believed to be an essential mechanism of diabetic 
complications. In diabetic patients, particular cell types are more susceptible to 
hyperglycemia than other cell types, such as endothelial cells and mesangial cells. The reason 
is that most cells are able to reduce glucose uptake when they are exposed to high glucose 
environment to keep a constant glucose levels inside the cells. However, cells that are 
damaged by hyperglycemia are those cannot reduce the glucose uptake efficiently, that lead 
to high glucose concentration inside the cells [10, 198]. How high intracellular glucose levels 
cause oxidative damage will be discussed below:  
1.4.1 Polyol pathway activation 
Polyol pathway is mainly catalyzed by aldose reductase (AR) reducing toxic aldehydes to 
inactive alcohols. However, when the glucose concentration is high in the cell, aldose 
reductase also starts reducing glucose to sorbitol [10]. Under normal condition, polyol 
pathway is only in charge of approx. 3% glucose metabolism [199], whereas it increases to 
30% under hyperglycemia condition [200]. This process consumes NADPH, and thus 
affecting the activities of NADPH dependent antioxidant systems such as Trx and GSH 
systems [10]. As a result, hyperglycemia would increase susceptibility of the cells to 
oxidative stress. Indeed, endothelial cells cultured in high glucose medium are shown to have 
increased sensitivity to H2O2 treatment with a reduced GSH level [201]. Aldose reductase is 
found in nerve, retina, glomerulus and vascular tissues, which are all hyperglycemia sensitive 
[202]. Increased NADPH consumption in these cells through reducing high amount of 
glucose to sorbitol causes oxidative stress. Study shows that diabetic dogs decrease nerve 
conduction velocity over time as it does in humans. However, five years aldose reductase 
inhibitor treatment prevents this defect in the diabetic dogs [203].   
1.4.2 AGE formation 
Advanced glycation end products (AGEs) are formed by glycation reaction, which refers to 
the addition of glucose or other glycating products from glucose to proteins or lipids through 
non-enzymatic reaction [204, 205]. Under hyperglycemia, the intracellular production of 
AGE precursors, such as glyoxal, methylglyoxal and 3-deoxyglucosone [206], is increased, 
which leads to glycation of intracellular proteins and causes cellular dysfunction. Further, 
intracellular AGE precursors can diffuse out of the cells, modify and cross-link the 
extracellular matrix [207]. The circulating proteins modified by AGE precursors bind to 
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receptors of AGE (RAGE), inducing ROS production and NF-κB activation. This 
subsequently causes series pathological changes in gene expression [208].    
1.4.3 Protein kinase C activation 
Protein kinase C (PKC) is widely expressed in mammalian cells and phosphorylates a 
number of target proteins. It is well known that high glucose level enhances the de novo 
synthesis of diacylglycerol (DAG), which activates PKC [209-212]. PKC dependent 
activation of NADPH oxidases (NOX) and ROS production have been reported in different 
studies. High glucose exposed smooth muscle cells and endothelial cells produce significant 
higher amount of ROS than those cultured in low glucose. Either PKC inhibitor or NOX 
inhibitor completely blocks the elevated ROS production [213]. Endothelial cells exposed to 
high glucose reveal enhanced formation of nitrityrosine and 8-hydroxydeoxyguanosine (8-
OHdG) with overexpressed NOX components as well as increased apoptosis. PKC inhibitor 
reduces nitrotyrosine levels, decreases 8-OHdG concentrations and attenuates cell apoptosis 
under such condition [214]. These findings indicate a high glucose induced PKC-dependent 
NOX activation, which enhances ROS production.     
1.4.4 Mitochondrial superoxide production 
As introduced in section 1.2.1, when glucose is metabolized through mitochondrial oxidative 
phosphorylation, it undergoes tricarboxylic acid (TCA) cycle and generates electron donors, 
such as NADH and FADH2. Electrons are transferred from the donors through the complexes 
of mitochondrial electron transport chain, which generates proton gradient across the 
membrane. The energy from this gradient voltage will either be used by ATP synthase for 
ATP synthesis or dissipated by uncoupling proteins (UCPs) for heat generation. In cells 
exposed to high glucose, there is overload of TCA cycle and over production of NADH and 
FADH2. The excessive electron flow will saturate the electron transfer capacity in the 
complexes of mitochondrial electron transport chain and increase the voltage gradient to 
reach a critical threshold. At this point, the complex III will be blocked, and single electron 
leakage from complex I, coenzyme Q or complex III will occur to reduce O2 to superoxide 
[10, 198].  Expressing UCP1 or MnSOD in the vascular endothelium blocks ROS production 
under hyperglycemia condition [215]. Depletion mitochondrial DNA from endothelial cells 
results in functional deficiency on mitochondrial electron transport chain and causing the loss 
of ROS production in these cells under hyperglycemia [10]. It also shows that inhibitors of 
mitochondrial electron transport chain complex I, complex II or mitochondrial pyruvate 
transporter inhibit high glucose promoted ROS production in rat kidney proximal tubular 
cells [216].      
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Taken together, high intracellular glucose concentration induces ROS production through 
polyol pathway activation, AGE formation, PKC activation and mitochondrial respiration 
(Fig. 7). 
 
Figure 7. High glucose induced oxidative stress. High glucose circumstance or 
hyperglycemia causes high intracellular glucose concentration in certain cell types and 
activates four pathways to increase ROS production. Activated polyol pathway catalyzed by 
AR (aldose reductase) reduces excessive amount of glucoses to sorbitols and over consumes 
NADPH, which inhibits NADPH-dependent antioxidant systems and causes ROS production. 
Increased glucose metabolism promotes the formation of glyceraldehyde 3-phosphate (G3P), 
which enhances the de novo synthesis of DAG (diacylglycerol), thereby leading to PKC-
dependent NOX activation and ROS production. AGE precursors formed by glucose 
metabolism diffuse into extracellular environment and glycate circulating proteins to form 
AGEs, which subsequently binds to RAGE (receptors of AGE) and induces ROS formation. 
Electron leakage from mitochondrial electron transport chain serves as an important source of 
ROS and will be exaggerated with access to high glucose.   
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1.5 ADIPOCYTE DIFFERENTIATION  
1.5.1 Adipose tissue and adipocyte differentiation   
Traditionally, adipose tissue is considered to be an inert mass that passively stores energy. 
However, adipose tissue is now identified as a complex and highly active metabolic organ 
with essential endocrine functions. Adipose tissue secrets many circulating factors including 
plasminogen activator inhibitor-1, leptin, adiponection, resistin, and protein of renin-
angiotension systemm etc. These hormones regulate variety of processes as homeostasis, 
blood pressure, immune function, angiogenesis and energy balance [217, 218]. Metabolic 
defects caused by either excessive or deficient adipose tissue illustrate the importance of 
endocrine function derived from adipose tissue. Obesity is usually associated with 
morbidities such as insulin resistance, hyperglycemias, dyslipidemia, proinflammatory and 
hypertension, which are known as metabolic syndrome [219]. On the other hand, adipose 
deficiency also correlates with features of metabolic syndrome [220].   
Adipose tissue is composed of connective matrix, nerve tissue, stromo-vascular cells, 
immune cells and most importantly, adipocytes [217]. Adipogenesis refers to the process that 
mesenchymal stem cells differentiate into adipocytes. This differentiation process is divided 
into two phases. The first phase is known as determination, results in conversion of 
multipotent cells into pre-adipocyte, which maintains its original morphology but loses the 
potential to differentiate into other cell types. The second phase is known as terminal 
differentiation, in which the pre-adipocytes acquire the mature adipocyte characteristics 
[218]. There are two types of adipocytes in mammals, named white and brown adipocyte 
respectively. Compared to white adipocytes, brown adipocytes accumulate smaller lipid 
droplets and contain a much higher number of mitochondria, which make it look brown 
[218]. In addition to the genes that are expressed in white adipocytes, brown adipocytes also 
express some distinct genes such as uncoupling protein-1 (UCP1), which uncouples the 
proton potential in mitochondria respiration and facilitates energy to be dissipated as heat 
without ATP synthesis [221].    
Adipocyte differentiation involves in activation of a series of transcription factors and 
signaling events that work in orchestra to drive the initiation and maturation of adipocytes.  
1.5.2 PPARγ  
PPARγ  belongs to the nuclear receptor superfamily and acts as a master regulator of 
adipocyte differentiation [218]. Overexpression of PPARγ is capable of inducing adipocyte 
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differentiation in cultured fibroblasts, on the contrary, genetic disruption of PPARγ impairs 
the development of adipose tissue in mice dramatically [222, 223]. So far, no factor has been 
identified to promote adipocyte differentiation in absence of PPARγ, and most adipogenesis 
inducers are found to at least partially activate PPARγ expression or activity [218]. PPARγ is 
shown to be not only important for adipogenesis, but also crucial for maintenance of 
adipocyte maturation. Overexpression of dominant-negative PPARγ into mature adipocytes 
results in de-differentiation with decrease of lipid content and adipocyte marker expression 
levels [224]. There are two isoforms of PPARγ,  γ1 and γ2. Both γ1 and γ2 mRNA are 
expressed abundantly in adipose tissue and found in skeletal muscle, whereas γ1 is also 
detected in liver, spleen and heart [225].  
The endogenous PPARγ ligand remains unclear. Earlier studies suggest different metabolites 
having ligand activity for PPARγ activation, including 15-deoxy-Δ12,14-prostaglandin J2 
(15d-PGJ2), certain polyunsaturated fatty acids, nitro unsaturated fatty acid, and oxidized 
low-density lipoprotein (oxLDL) etc [226-230]. However, these biological ligands bind to 
PPARγ with relatively low affinity (Kd = 2-50 µM), compared with the affinity (normally Kd 
< 1 nM) for most endogenous ligands for nuclear receptors [231]. Similar to other nuclear 
receptors, PPARγ binds to DNA together with retinoid X receptor as a heterodimer. It shows 
that PPARγ-responsive element consist of two repeats of "AGGTCA" separated by a single 
nucleotide [231].  
1.5.3 C/EBP family 
Six isoforms of C/EBP proteins have been identified and all of which act as homo and/or 
heterodimers via a bZIP domain [232]. Many of them are involved in adipocyte 
differentiation, among which C/EBPβ and C/EBPα are the most essential players. The 
expression pattern of these transcription factors during the progress of adipocyte 
differentiation indicates a signaling cascade whereby expression of C/EBPβ in early stage of 
differentiation leads to induction of C/EBPα [233].  
C/EBPβ gene produces different isoform proteins; liver-enriched activator protein (LAP) is 
the transcriptional active form, whereas liver-enriched inhibitory protein (LIP) is a truncated 
form that negatively regulates the LAP activity [234]. Ectopic expression of C/EBPβ in 3T3-
L1 preadipocytes is able to induce adipocyte differentiation without hormonal treatment 
[235]. Further, forced expression of C/EBPβ in NIH-3T3 fibroblasts induces 
PPARγ expression and promotes adipogenesis upon differentiation induction [236]. Mitotic 
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clonal expansion (MCE) refers to the process that post-confluent cells undergo one or two 
rounds of cell division upon treatment of differentiation inducing agents, which is a 
prerequisite for in vitro differentiation of mouse embryonic fibroblasts (MEFs) and mouse 
preadipocytes 3T3-L1 [237, 238]. C/EBPβ is shown to be essential for MCE, MEFs with 
C/EBPβ knockout neither undergo MCE nor differentiate to adipocytes upon induction. 
However, overexpression of C/EBPβ (LAP) but not dominant-negative C/EBPβ (LIP) in the 
knockout MEFs restores MCE and adipogenesis [238]. C/EBPβ and C/EBPδ deficient MEFs 
have severely defected adipocyte formation with no C/EBPα and PPARγ expression. Mice 
lacking C/EBPβ developed normal WAT with reduced lipid accumulation in BAT. On the 
other hand, mice with C/EBPβ and C/EBPδ double knockout have impaired adipose tissue 
development [239].  
C/EBPα also plays an important role in adipogenesis and directly induces adipocyte genes. 
Ectopic expression of C/EBPα in various mouse fibroblasts promotes adipocyte 
differentiation without hormonal induction [240]. Expression of C/EBPα antisense RNA in 
3T3-L1 preadipocytes suppresses adipocyte genes expression, lipid accumulation and 
adipogenesis in these cells [241]. Homozygous C/EBPα knockout causes early lethality after 
the birth of mice, due to defective liver gluconeogenesis and subsequent hypoglycemia [242, 
243]. Restoration of hepatic C/EBPα expression rescues the mice and shows limited effects 
on BAT. However, the WAT is almost absent in these mice with excessive lipid levels in 
serum, suggesting that C/EBPα is required for WAT development in vivo [243].    
1.5.4 Insulin signaling in adipocyte differentiation 
Insulin signaling has remarkable effects on adipocyte differentiation. It stimulates glucose 
uptake and lipid synthesis, which are important for adipocyte metabolism [244]. Mouse 
fibroblasts and brown preadipocytes that have inactivated insulin receptor (IR) or IR 
deficiency show dramatically impaired ability to differentiate into adipocytes [245, 246]. 
However, the link between insulin signaling and adipocyte differentiation is complex, with 
many downstream signaling events involved. The knockout of individual insulin receptor 
substrates in brown preadipocytes demonstrates that IRS-1 is the most important IRS for 
adipogenesis with a severe defect in this process upon depletion. IRS-3 knockout also shows 
moderate influence on adipogenesis, but no effect observed from IRS-2 or IRS-4 knockout 
[247]. Phosphatidylinositol-3 kinase (PI3K) and protein kinase B (Akt/PKB) pathway plays 
an essential role in downstream of insulin signaling cascades, and are also crucial for 
adipogenesis. Mice lacking Akt2/PKBβ exhibit an age-dependent loss of adipose tissue and a 
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dramatic reduction of adipose depots by 22 weeks of age [248]. Another downstream player, 
mammalian target of rapamycin (mTOR) is also involved in adipocyte differentiation. Using 
rapamycin to inhibit mTOR kinase activity blocked adipocyte differentiation through 
inhibition of the transcription activity of PPARγ [249]. Insulin signaling can also activate and 
phosphorylate cyclic AMP response element-binding (CREB) protein, which is reported to be 
a primary transcription factor that promotes the initiation of adipogenesis [250, 251].   
The phosphatases that negatively regulate insulin signaling also have enormous impact on 
adipocyte differentiation. Protein-tyrosine phosphatase 1B (PTP1B) is shown to directly 
inhibit insulin signaling by suppressing the phosphorylation of insulin receptor [252]. In 
addition, PTP1B deficient brown preadipocytes undergo an accelerated adipogenesis with 
upregulation of PPARγ and adipogenic markers [253]. Phosphatase and tensin homologue 
(PTEN) dephosphorylates and converts phosphatidylinositol (3,4,5)-trisphosphate (PIP3) to 
phosphatidylinositol (4,5)-bisphosphate (PIP2), so that inhibiting the activation of Akt/PKB. 
Liver specific PTEN knockout results in increased phosphorylation of Akt/PKB, fatty liver 
and induction of adipocyte-specific genes, implying adipogenic transformation in the liver 
[254, 255].  
1.5.5 Redox regulation in adipocyte differentiation  
Many studies have shown that intracellular ROS is important modulating factor in adipocyte 
differentiation. Evidence shows that NADPH oxidase contributes as a major source of ROS 
during adipocyte differentiation in 3T3-L1 preadipocytes [256]. Inhibiting NADPH oxidase 
using inhibitor or si/shRNA attenuates ROS production and adipocyte differentiation [257, 
258]. In human mesenchymal stem cells, an early increase of ROS derived from 
mitochondrial metabolism is shown to be essential for adipocyte differentiation. Antioxidants 
that target mitochondria suppress adipocyte differentiation, which is then rescued by 
exogenous H2O2 treatment [259]. Further, inhibiting mitochondrial activity by rotenone or 
siRNA knockdown of the mitochondrial transcription factor A (TFAM) causes significant 
adipocyte differentiation suppression [260]. NO also has a vital role in adipocyte physiology. 
Rat preadipocytes are found to produce 50% more NO during the initiation of adipocyte 
differentiation. Deprivation of endogenous NOS activity by NOS inhibitor suppresses the 
differentiation process [261].  
There are different aspects from which ROS can regulate adipogenesis (Fig. 8). Accumulated 
evidence shows that ROS, especially H2O2 may act as secondary signaling messengers to 
enhance signaling transduction via oxidation and inactivation of phosphatases, which are 
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negative regulators of phosphorylation signaling cascades [19, 262-264]. ROS can also 
directly oxidize and activate Src tyrosine kinases, thereby activating Akt/PKB dependent 
signaling [265-267]. As discussed above, MCE is an essential process for in vitro 
differentiation of MEFs and preadipocytes 3T3-L1. H2O2 treatment accelerates cell cycle 
progression during MCE and facilitates adipocyte differentiation in 3T3-L1 cells. Further, 
oxidative stress increases the oxidation and dimerization of C/EBPβ, which subsequently 
enhances its DNA binding capacity [268]. Another redox regulated adipogenesis signaling 
molecule is the master regulator PPARγ, of which the activation is ligand dependent. Nitro-
modified unsaturated fatty acids are recently found to be relatively potent endogenous PPARγ 
ligands that activate PPARγ at sub-micromole concentration with increased production under 
oxidative stress [269].     
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Figure 8. Redox regulation in adipocyte differentiation. Insulin signaling activates 
downstream PI3K/Akt pathway, which further activates downstream events that connected to 
PPARγ, the master regulator of adipocyte differentiation. Intracellular ROS promotes 
adipogenesis from different aspects. ROS oxidizes and inactivates phosphatases, such as 
PTP1B and PTEN, to enhance the insulin signaling cascades. In addition, ROS also oxidizes 
and activates Src kinase, thereby activating Akt/PKB. Moreover, ROS enhances the activity 
of C/EBPβ and accelerates the MCE, which are important factors for the initiation of 
adipogenesis. Endogenous PPARγ ligands production can also be promoted by ROS 
accumulation.   
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2 AIMS OF THIS THESIS 
Mammalian TrxR1 is importantly involved in DNA synthesis, antioxidant defense and 
maintenance of cellular redox homeostasis. However, the necessity of Sec in TrxR1 is not 
clear. Here we first wish to study the unique cellular functions and properties of the natural 
Sec-containing TrxR1 compared to its Cys-containing counterpart. In addition, TrxR1 has 
been implied to play a crucial role in redox regulation; we thereby wish to investigate the 
impact of TrxR1 in redox sensitive signaling events. Moreover, many cancer cells have 
upregulated antioxidant systems including TrxR1 to adapt to the increased oxidative stress, 
and several anticancer compounds used clinically or under clinical trails are shown to target 
TrxR1 as at least part of their cytotoxicity mechanism. Therefore, we wish to further 
investigate the role of TrxR1 as an anticancer target.  
 
Specific objective in each paper is to: 
Paper I 
Investigate the targeting effects of the mutant p53 activator and anticancer drug lead named 
APR-246 (PRIMA-1MET) on mammalian TrxR1.  
Paper II 
Study how the Sec content of mammalian TrxR1 modulates the cytotoxicity of drugs that 
target TrxR1 and the glutathione dependence of the cells.  
Paper III 
Explore the importance of Sec-containing TrxR1 to the growth and survival of mammalian 
cells.  
Paper IV      
Elucidate the role of TrxR1 in regulation of insulin signaling and adipocyte differentiation.  
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3 RESULTS AND CONCLUSIONS 
3.1 PAPER I 
Tumor suppressor p53 is for DNA repair, cell cycle arrest and apoptosis initiation. Several 
different types of DNA damage can activate p53, such as double-strand breaks in DNA 
produced by γ-irradiation, ultraviolet irradiation and chemical damage to DNA. In response 
to this, the transcription activity of p53 is activated to induce downstream genes, such as p21 
that causes cell cycle arrest. In addition, p53 can also initiate apoptosis in response to 
oncogene activation, and thus serves as a tumor suppressor [270]. It shows that p53 is 
inactivated in most human cancers, and direct gene mutations in p53 contribute to half of the 
inactivation [271]. Therefore, mutant p53 becomes a promising target for novel anticancer 
therapy.  
APR-246 (PRIMA-1MET) is converted to methylene quinuclidinone (MQ), a Michael acceptor 
that can covalently binds to Cys in p53, promotes the correct folding of mutant p53 and 
restores the wild-type p53 activity [272, 273]. Since mammalian TrxR1 has a Sec on its 
active site, which is much more reactive than Cys, we therefore wished to study the targeting 
effects of APR-246 on TrxR1.  
We found that APR-246 (active compound MQ) inhibited the activity of both recombinant 
and cellular TrxR in cells, with different p53 background. However, Sec-to-Cys mutant 
TrxR1 is resistant to this inhibition, suggesting that the targeting residue is the Sec in wild-
type TrxR1. Inhibited TrxR1 still maintains its NADPH oxidase activity, which causes 
massive ROS production. Indeed, knockdown TrxR1 attenuated APR-246 induced ROS and 
cell death independent of p53 status.  
This study demonstrates that targeting TrxR1 is an additional cytotoxicity mechanism of 
APR-246. The ability of targeting TrxR1 and restoring wild-type p53 activity in the tumor 
could produce a synergic effect that disrupts the cellular redox and activates apoptosis 
signaling cascades. Targeting TrxR1 in addition to mutant p53 will reduce the risk of 
resistance development, since long-term treatment with APR-246 may cause loss of mutant 
p53 expression. Taken together, this finding reveals the mechanism that APR-246 could 
potently and specifically target tumor cells in relative to normal tissues.  
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3.2 PAPER II 
In mammalian cells, SePO3 is used as the selenium source for Sec synthesis and 
incorporation into selenoproteins. However, it is reported that SPO3 might compete with 
SePO3 as a substrate of SecS, that leads to Cys synthesis and incorporation in the site of Sec 
residue on selenorptoens. This normally occurs under selenium deficient conditions [52, 53]. 
Study shows that using SPO3 to treat NIH 3T3 cells converts up to 96% of the TrxR1 to Cys-
containing variant. Based upon this, we wished to titrate the Sec content in TrxR1 using SPO3 
or selenite supplementation. We wondered how this would modulate the cytotoxicity of drugs 
that target TrxR1 and the glutathione dependence of the cells.  
In this study, we supplemented cells with different concentration of SPO3 or selenite, and 
subsequently measured total and specific cellular TrxR activities. It revealed that SPO3 
increased Cys incorporation into TrxR1. On the other hand, selenite promoted the expression 
of Sec-containing TrxR1. Meanwhile, we found that high concentrations of SPO3 (> 300 µM) 
were highly toxic to the cells. However, lower concentrations of SPO3 (100 - 300 µM), 
attenuated the cytotoxicity of cisplatin on both A549 and HCT116 cells. On the contrary to 
the cancer cells, which have increased cellular TrxR activity, NIH 3T3 cells showed low 
basal TrxR activity and were highly susceptible to GSH depletion. We thus used selenite to 
boost TrxR activity in these cells, and found the resistance to BSO treatment increased, 
whereas the resistance to cisplatin decreased. The obtained resistance to GSH depletion is in 
agreement with the literatures that there are complementary functions between Trx and GSH 
pathways, and under many conditions, either Trx or GSH system is sufficient enough to 
support the cellular redox homeostasis [103, 106, 157, 274].       
In summary, these results suggest that the selenium status of cells can affect the Sec 
incorporation into TrxR1, and thereby modulating the cytotoxicity of drugs that target TrxR1 
and the glutathione dependence of the cells.  
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3.3 PAPER III 
Since mammalian TrxR1 is synthesized as a Cys-containing counterpart under selenium 
starvation conditions, together with the fact that some organisms express a closely related 
Cys-containing TrxR, such as D. melanogaster [42], we wonder if the Sec is necessary for 
the cellular function of mammalian TrxR1, and whether there are any unique properties or 
cellular functions of Sec-containing TrxR1 compared to its Cys variant.   
In this study, we utilized a MEF cell line with TrxR1 knockout (Txnrd1-/- MEFs). Further, 
we stably overexpressed different variant of TrxR1 in the knockout cells. Immunoblotting, 
75selenium radioactive labeling and cellular enzymatic assay confirmed the successful 
construction of the knockout and mutant expressing TrxR1 MEF cell lines. We found only 
the TrxR1 null MEFs had significant activation of Nrf2, with unregulated Trx and GST 
activities as well as total GSH content. Therefore, it is not surprising that the TrxR1 
deficient cells are highly susceptible to GSH depletion with massive cell death. However, 
the TrxR1 mutant cells showed more resistance to BSO treatment than the knockout cells.  
We subsequently observed that when seeded in high density (> 8000 cells/cm2), all the cells 
grew normally regardless of the TrxR1 status. However, when seeded at lower density (< 
1000 cells/cm2), only cells that express Sec-containing TrxR1 could survive and proliferate, 
whereas the other cells underwent extensive cell death. Intriguingly, both conditioned 
medium from high-density culture and catalase supplementation were able to completely 
rescue the cell death of the knockout MEFs at low-density. This indicates that H2O2 is the 
toxic factor that kills the cells. Extracellular H2O2 measurement revealed that the TrxR1 
deficient MEFs secreted fourfold H2O2 compared with the parental wild-type MEFs 
(Txnrd1fl/fl MEFs). Expressing Sec-containing TrxR1 but not the Cys mutant enzyme in the 
knockout cells reverted the H2O2 release.  
DMEM medium with high-glucose (25 mM) is the standard medium for MEFs culturing 
[275], which is also the medium we use here. High glucose and hyperglycemia have been 
linked to induction of excessive amount of H2O2 and cause of oxidative damage [10]. We 
thus used DMEM with low-glucose (5 mM) and found that in sharp contrast to what was 
observed in high-glucose medium, the knockout MEFs survived and grew very well in the 
low-glucose medium. In addition, the oxidized Trx and activated JNK in the knockout 
MEFs in high-glucose was completely reversed when the low-glucose medium was used. 
This study shows that Sec-containing TrxR1, but not the Cys variant, is exclusively 
required for self-sufficiency of MEFs by control of glucose metabolism derived H2O2, 
which is not compensated by elevated GSH system.  
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3.4 PAPER IV 
Recent studies show that liver-specific deletion of Txnrd1 results in alterations of glycogen 
and lipid storage in liver [101, 102], which motivate us to investigate the nutrient storage in 
the knockout MEFs. We observed that Txnrd1-/- MEFs possess 2-folder higher triglyceride 
contents compared to the Txnrd1fl/fl MEFs. In addition, we are also curious about the 
adipocyte differentiation capacity in the MEFs with TrxR1 knockout. We found knocking out 
TrxR1 in the MEFs promotes adipocyte differentiation dramatically upon hormone induction 
with strongly upregulated PPARγ expression. The essential process for in vitro differentiation 
of MEFs, MCE, spontaneously occurred in the knockout MEFs without any treatment and 
became accelerated upon induction. However, complete cell cycle arrest without any 
indication of MCE was observed in the parental Txnrd1fl/fl MEFs. Insulin related signaling 
cascades Akt, CREB/ATF1 and S6 were more activated in the knockout cells upon 
differentiation stimulation. We thereafter found a reduced PTEN activity in the Txnrd1-/- 
MEFs, which may contribute to the Akt activation. Through overexpression wt but not active 
site mutated PTEN in the knockout cells, we were able to attenuate the Akt activation and 
adipocyte differentiation when subjected to hormone treatment.  
We showed that p27, a cell cycle arrestor, was downregulated and destabilized in the 
knockout cells, which is due to the activated Akt that inhibits the expression and induces the 
degradation of p27. The reduced p27 thus stimulated MCE and adipocyte differentiation in 
the knockout cells. NAC treatment inhibited Akt activation, stabilized p27, and thus blocked 
MCE and adipocyte differentiation. We found NAC treatment did not further increase but 
even decrease the total GSH levels in the knockout cells. Therefore, the effects of NAC are 
likely come from its intrinsic antioxidant activity. 
Another mechanism contributes to enhanced adipocyte differentiation in the knockout MEFs 
is their 30-fold increased PPARγ mRNA levels compared to the parental cells. Recent studies 
show that unsaturated fatty acids modified by NO might be potent endogenous PPARγ 
ligands that can be furthermore produced upon oxidative stress [229, 269, 276]. Therefore, it 
is plausible that the Txnrd1-/- MEFs with higher oxidative stress have much higher PPARγ 
expression. Here we found nitrooleate (AONO2) indeed induced adipocyte formation in the 
knockout cells. To validate our findings in MEFs, we isolated pre-adipocytes from human 
and differentiated them in vitro. We observed that knockdown TrxR1 significantly increased 
adipogenesis in these human cells as well. We conclude that TrxR1 suppresses adipocyte 
differentiation through inhibiting insulin signaling cascades, MCE and PPARγ expression 
(schemes summarizing these findings are shown in Fig. 9 of Paper IV). 
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3.5 DISCUSSION AND FUTURE PERSPECTIVE 
This thesis further explored the role of TrxR1 as an anticancer target, and investigated the 
modulation effects of the Sec residue on the cytotoxicity triggered by TrxR1 inhibitor. We 
also unveiled that Sec-containing TrxR1 is required for the self-sufficiency of MEFs under 
high-glucose condition due to the control of glucose derived H2O2, which is not compensated 
by upregulated GSH system. This is, to our knowledge, the first time a crucial Sec-dependent 
role of TrxR1 identified for mammalian cells. We subsequently showed that TrxR1 
suppresses adipocyte differentiation through negatively regulating insulin signaling, MCE 
and PPARγ expression, which indicates an important role of TrxR1 in glucose homeostasis 
and physiology of adipose tissue in vivo.  
In paper I, we found that the mutant p53 activator APR-246 (PRIMA-1MET) also targets and 
inhibits TrxR1, converts the enzyme to a dedicated NADPH oxidase. It reports earlier that a 
wild-type p53 activator RITA, which prevents the interaction between MDM2 and p53, also 
inhibits TrxR1 and contributes to its apoptosis induction. Long-term treatment with a single 
drug may apply a specific selection pressure on the tumor and results in resistance 
development. Combination treatment of APR-246 and RIPA would activate mutant p53 and 
prevent p53 degradation at the same time, together with TrxR1 inhibition, this treatment 
might have synergic effects on killing cancer cells and minimize the resistance development.     
In addition, this study further strengthens the principle that targeting TrxR1 seems to be an 
intriguing anticancer strategy. As discussed before, TrxR1 contains a Sec in its C-terminal 
active site, which is more reactive than Cys with a much higher nucleophilicity. Further, the 
C-terminal Sec-containing active site of TrxR1 is exposed and easily accessible [277], 
whereas the Sec residues of the other major selenoprotein family Gpxs are embedded [278]. 
In addition, cancer cells normally have increased ROS levels compared to their normal 
counterparts [122, 123], which require upregulation of antioxidant systems including TrxR1 
to maintain the cellular redox balance. Targeting Sec residue on TrxR1 inhibits its enzymatic 
activity and converts this enzyme to a NAPDH oxidase with increased ROS production. 
Since cancer cells are more reliable on cellular antioxidant capacity and more susceptible to 
oxidative stress, inhibiting TrxR1, especially selectively targeting the Sec residue, is likely to 
be much more toxic to cancer cells than healthy tissues. Based upon this, we screened approx. 
400,000 compounds and identified a novel TrxR1 inhibitor with high potency and specificity. 
This inhibitor showed anticancer efficacy in different mouse models in vivo without having 
apparent toxicity in normal tissues [Stafford et al., manuscript in preparation]. Further 
development on this compound is in progress.     
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In paper II, we found that increased Sec incorporation into TrxR1 sensitized the cells to 
cisplatin treatment, whereas elevated expression of the Cys variant of TrxR1 render the 
cancer cells resistant. The connection between body Se status and cancer has been implicated 
for many years [279]. It appears that to reach the serum selenium levels that are optimal for 
the activity and expression of Gpx3 and selenoprotein P could reduce the incidence of various 
types of cancer [280]. Long-term selenium supplementation in participants from the Chinese 
region of Qidong with low selenium in the soil reduced the incidence of primary liver cancer 
[281]. The Nutritional Prevention of Cancer (NPC) trial showed that only the men with low 
basal levels of plasma selenium had a decreased prostate and colorectal cancer when 
subjected to selenium supplementation [282]. In another Phase III trial, the prostate cancer 
incidence was decreased (non-significantly) in the selenium-supplemented men with the 
lowest group of basal plasmas selenium levels [283]. A Spanish study found significant lower 
selenium levels in the patient group with high incidence of colerectal adenomas or colerectal 
cancer having the age below 60 years [Spanish]. On the contrary, the famous Selenium and 
Vitamin E cancer Prevention Trial (SELECT) showed neither selenomethionine nor vitamin 
E prevented prostate cancer with the age above 50 years. It is likely due to the considerably 
high basal plasma levels of selenium in the SELECT participants with a mean value above 
the optimal concentration for the activity and expression of the plasma selenoproteins Gpx3 
and selenoprotein P [280, 284]. The possible mechanism of the selenium protection effects 
might be due to its modulation on the activities of selenoproteins, such as selenoprotein P, 
TrxR and Gpxs, which suppress the ROS mediated Akt signaling and DNA mutation [280].  
Likewise, early epidemiological studies showed that the selenium levels in serum, plasma, 
and urine are lower in various types of cancer patients compared to that in the controls [285]. 
Thus, the selenium deficiency in cancer patients is likely to induce Cys variant TrxR1 
expression, which may cause resistance to electrophilic compound treatment that has TrxR1 
inhibition as part of its efficacy mechanism. Chemotherapy in combination with selenium 
supplementation might be a solution to this type of resistance. To approve this, additional in 
vivo studies are needed: mice with tumor xenografts can be fed with either selenium 
sufficient or deficient diet, and then the anticancer efficacy of cisplatin will be compared. 
Besides, the cytotoxicity on normal tissues should also be taken into consideration; for 
example, the nephrotoxicity triggered by cisplatin will also be evaluated under different 
selenium status.  
In paper III, we observed that Sec-containing TrxR1 is required for the survival and growth 
of MEFs under high glucose condition when cultured at low density, due to the important 
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elimination of glucose-derived H2O2. This is, to our knowledge, the first time a unique and 
essential Sec-dependent role of TrxR1 identified for mammalian cells. Insulin resistance 
caused by genetic variants, aging or obesity results in high blood glucose in the body. To 
maintain glucose homeostasis, expansion of pancreatic β cell mass by cell growth and 
enhancement of β cell function usually occur to compensate insulin resistance through 
increase of insulin secretion. Nevertheless, after long time exposure to hyperglycemia, β cells 
become defective and ultimately failed mainly due to the oxidative damage triggered by 
hyperglycemia. The onset of β cell failure accompanied with insulin resistance indicates the 
development of type 2 diabetes [286]. The results from this study imply that TrxR1 might 
play a key role in antioxidant defense of pancreatic β cells against this oxidative damage. 
Direct modulation of TrxR1 expression level and selenium supplementation will be used in 
culture of primary pancreatic islet and the β cell lines, thereafter the cell growth and cell 
death will be evaluated under high glucose condition. In addition, (db/db) mice that are 
lacking of leptin receptor and usually used as mouse model for study of obesity-induced 
diabetes. By constructing pancreatic β cell-specific Txnrd1 knockout (db/db) mice, we will be 
able to investigate if TrxR1 is involved in the protection of β cells against hyperglycemia 
induced oxidative damage in vivo. β cell failure will be assessed by monitoring insulin 
secretion in pancreatic β cell-specific Txnrd1 knockout (db/db) mice compared to control 
(db/db) mice. Measurement of β cell mass and detection of cell death markers will further 
validate and characterize the β cell failure. Thus, this project has a potential to provide new 
insights into the role of TrxR1 in antioxidant defense in the development of type 2 diabetes, 
and to yield innovative prevention solutions to type 2 diabetes. 
In paper IV, we found TrxR1 suppresses adipocyte differentiation through inhibiting insulin 
signaling cascades, MCE and PPARγ expression. Early studies show that germline depletion 
of Txnrd1 results in embryonic lethality [96, 97]. This is less likely caused by the deficiency 
in cell proliferation since the embryos underwent several rounds of proliferation and 
accumulated thousands of cells before they died. It is believed that the alteration of cellular 
signaling events in TrxR1 deficient cells induced this lethality. Recent studies demonstrate 
that liver-specific TrxR1 knockout influences glycogen and lipid storage in this organ, 
indicating a metabolic alteration upon Txnrd1 disruption [101, 102].  The present study 
reveals that TrxR1 plays an essential role in redox regulation of insulin signaling cascades 
and adipocyte differentiation. In addition to these signaling pathways, more cellular signaling 
cascades can be affected upon removal of TrxR1. Thus, it is plausible that the embryonic 
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lethality triggered by depletion of Txnrd1 is due to the disordered redox cellular signaling that 
causes the defects in embryonic development.  
It appears that TrxR1 has dual roles in cancer. Accumulated indications imply that TrxR1 
serves as a tumor suppressor in normal tissues preventing transformation and cancer 
initiation. High ROS levels cause DNA damage, thereby triggering DNA mutation and 
oncogenetic transformation [287]. Moreover, ROS can oxidize Src kinases and activate Akt 
signaling, which promotes cell survival, cell proliferation and facilitate carcinogenesis. 
Through ROS scavenging, TrxR1 could prevent DNA mutation and transformation. Further, 
as discussed before and also showed in this study, TrxR1 is important for the maturation and 
function of p53, which is a strong tumor suppressor that induces cell cycle arrest and 
apoptosis. PTEN is another important tumor suppressor that negatively regulates Akt 
pathway [288]. The present study demonstrates that depletion of Txnrd1 causes reduction of 
PTEN activity and activation of Akt signaling, suggesting that TrxR1 also supports cellular 
PTEN function. Taken together, in additon to removal of ROS, TrxR1 suppresses cancer 
initiation through supporting the functions of tumor suppressors. This theory is endorsed by 
recent study showing that tissue-specific knockout of TrxR1 increases the chemical induced 
hepatocarcinogenesis [102].  
To our knoledge, it is the first time that a role of TrxR1 in regulation of adipocyte 
differentiation and insulin signaling cascades identified, however, animal studies are requried 
to further analyze how TrxR1 regulate glucose homeostasis and adipose physiology in vivo. 
Since TrxR1 knockout mice are embryonically lethal, adipose- and/or muscle-specific 
knockout of TrxR1 can be used to study the roles of TrxR1 on adipogenesis and insulin 
sensitivity in vivo. The mice will be feeded with standard chow diet (SCD) or high fat diet 
(HFD), and subsequently total body mass, fat mass, glucose tolerant test (GTT), insulin 
tolerance test (ITT), fasting glucose level, and fasting insuin level etc. will be compared 
between wild-type and knockout mice. In the knockout MEFs with adipocyte differentiation, 
we found small lipid droplets accumulated with upregulation of UCP1 expression, indicating 
brown adipocyte features. However, in vivo data are needed to further validate and confirm 
whether it is white or brown adipocyte induced by TrxR1 knockout. Through these animal 
studies, we will obtain deeper insights into the role of TrxR1 in regulation of glucose 
homeostasis and adipose physiology, which might yeild to novel strategies for treatment of 
type 2 diabetes and prevention of obesity.          
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